![](https://library.celltelligence.com/wp-content/uploads/2022/12/Screenshot-2022-12-01-at-21.13.36.png)
$0
Allogene’s R&D Showcase 2022: Celltelligence Analysis – Part 1
On Tuesday, November 29, Allogene held an R&D showcase (press release / presentation) providing updated clinical milestones and results from ALLO-501A (allogeneic CD19 CAR-T) and ALLO-715 (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on the new data presented by Allogene from its hematology franchise, while discussing potential regulatory timelines for ALLO-501A and how it could compete with approved autologous CAR-Ts.